The small proportion of nurses in the U.S. respondent pool also may have affected this rating because, as is widely known, most event reports originate from nurses [ 26].
Failure to administer or incorrect dosage were the most common events reported [ 2].
Most adverse events reported to be mapatumumab related were mild to moderate in severity.
Most adverse events reported in this study occurred during the maintenance phase of the treatment period (Table 8).
The most frequent adverse events reported were coughing, diarrhoea, vomiting, abdominal pain and loss of appetite.
The most frequent adverse events reported were coughing, diarrhoea, vomiting, loss of appetite and abdominal pain.
The most common adverse events reported were headache, cough, abdominal pain, coryza, skin rash, nausea, vomiting, and diarrhea.
The most common adverse events reported in trials were nausea, vomiting, diarrhea, dizziness, and weight loss.
The most notable adverse events reported were transient gastrointestinal symptoms and skin rash.
Infections are the most common adverse events reported in literature related to TNF-α antagonists.
